Kotani Satoshi, Kohge Naruaki, Tsukano Kousuke, Ogawa Sayaka, Yamanouchi Satoshi, Kusunoki Ryusaku, Aimi Masahito, Miyaoka Youichi, Fujishiro Hirofumi
Department of Endoscopy, Shimane Prefectural Central Hospital.
Department of Gastroenterology, Shimane Prefectural Central Hospital.
Nihon Shokakibyo Gakkai Zasshi. 2017;114(10):1853-1859. doi: 10.11405/nisshoshi.114.1853.
Platelet transfusions are generally administered to patients with liver cirrhosis and associated thrombocytopenia before radiofrequency ablation (RFA). Here, we describe a 77-year-old woman who was diagnosed with hepatitis C, liver cirrhosis, and hepatocellular carcinoma (HCC) in 2006. She underwent RFA in October 2014 and October 2015, with platelet transfusions. She was admitted to our hospital in July 2016 to receive RFA for recurrence of HCC. To avoid platelet transfusion before RFA, she was administered lusutrombopag. The platelet count increased, and she did not need a platelet transfusion. In November 2016, computed tomography revealed that HCC had recurred. Lusutrombopag was readministered to avoid platelet transfusion before performing RFA. Subsequently, her platelet count increased, platelet transfusion was avoided, with no side effects. The results obtained in this case are valuable because there is little information on readministration of lusutrombopag.
对于肝硬化合并血小板减少症的患者，通常在进行射频消融术（RFA）之前给予血小板输注。在此，我们描述一位77岁女性，她于2006年被诊断为丙型肝炎、肝硬化和肝细胞癌（HCC）。她在2014年10月和2015年10月接受了RFA治疗，并伴有血小板输注。2016年7月，她因HCC复发入住我院接受RFA治疗。为避免在RFA之前进行血小板输注，给予她芦曲泊帕。血小板计数升高，她无需进行血小板输注。2016年11月，计算机断层扫描显示HCC复发。再次给予芦曲泊帕以避免在进行RFA之前进行血小板输注。随后，她的血小板计数升高，避免了血小板输注，且无副作用。该病例所获得的结果具有价值，因为关于芦曲泊帕再次给药的信息很少。
